The United Kingdom is a global leader in dementia research, with 2026 representing a pivotal year for clinical breakthroughs. Research has shifted significantly toward early detection through blood biomarkers and the integration of digital health solutions to monitor brain health in real time. For patients and families, these trials offer an opportunity to access cutting edge diagnostics and contribute to the development of disease modifying treatments that aim to slow or prevent the progression of cognitive decline.
Currently, the clinical focus is on validating low cost, accessible diagnostic tools that can be used in primary care settings. This movement is supported by government funding and partnerships between the NHS, charitable organisations, and private research foundations. This guide outlines the most prominent trials currently active in the UK and explains how individuals can get involved in shaping the future of dementia care.
what we will discuss in this article
- The launch of the Bio-Hermes-002 finger prick blood test study
- The Blood Biomarker Challenge including the ADAPT and READ OUT trials
- Digital health innovations and the use of AI in home monitoring
- The role of the UK Dementia Research Institute in emerging therapies
- How to use Join Dementia Research and the NHS App to find trials
- Clinical goals for amyloid and tau protein detection
- emergency guidance for identifying signs of health deterioration
Bio-Hermes-002: The finger prick blood test trial
A major international study called Bio-Hermes-002 was launched with significant recruitment centers across the UK.
This trial is investigating whether a simple, low cost finger prick blood test can accurately detect the early stages of Alzheimer disease before symptoms even begin. The study focuses on three key proteins: pTau217, GFAP, and NfL. These markers indicate the buildup of Alzheimer pathology, brain inflammation, and neurodegeneration. By comparing these finger prick results with gold standard brain scans and cognitive tests, researchers aim to prove that this minimally invasive method can replace expensive and time consuming PET scans or lumbar punctures.
The Blood Biomarker Challenge: ADAPT and READ OUT
The Blood Biomarker Challenge is a clinical program designed to revolutionize dementia diagnosis within the NHS.
The ADAPT Study
Led by University College London, the ADAPT trial is currently recruiting over 1,000 participants through NHS memory clinics. It specifically examines a blood test that measures p-tau217. The goal is to determine if providing these results to clinicians early in the assessment process can speed up diagnosis and lead to more accurate treatment plans.
The READ OUT Study
This study focuses on the validation of various blood markers and their cost effectiveness. It aims to provide the necessary clinical and economic data to justify the rollout of blood tests across the entire NHS. By participating in these trials, patients are helping to build the evidence base needed to make early diagnosis a standard part of healthcare.
Digital health and home monitoring research
Clinical research is increasingly exploring how technology can support people with dementia in their own homes.
The UK Dementia Research Institute and various spinout companies are trialling technologies such as:
- Smartphone Based Assessments: Using apps to perform regular, short cognitive tests that are analysed alongside blood biomarkers.
- Ambient Sensors: Using cameras and motion sensors to detect subtle changes in daily routines that may indicate the early stages of cognitive decline.
- AI Personal Assistants: Testing smart speakers that learn a person enjoyments and cognitive abilities to provide reminders and brain training exercises.
These trials are essential for moving dementia care out of the hospital and into the community, allowing for more personalized and less intrusive monitoring.
How to participate in UK research
The UK has streamlined the process for volunteers to find and join research studies through centralized digital platforms.
| Platform | Role in Research | How to Access |
| Join Dementia Research | Matches volunteers to suitable studies nationwide | Online registration or via phone |
| NHS App | Browsing and signing up for clinical trials directly | Digital front door via smartphone |
| Be Part of Research | National service for all clinical conditions | Website registration |
| Memory Clinics | Direct referral to active local trials | Clinical consultation with your GP |
Anyone over the age of 18 can register, whether they have a dementia diagnosis or not. Healthy volunteers are especially needed as controls to help researchers understand the differences between normal aging and the early stages of neurodegeneration.
To summarise
UK dementia research in 2026 is defined by a push toward faster, more accurate, and less invasive diagnostics. The Bio-Hermes-002 and ADAPT studies represent a major leap forward in identifying the biological signs of Alzheimer disease through simple blood tests. Alongside these, digital innovations are providing new ways to monitor brain health at home. For patients, participating in these trials provides hope and access to the latest medical advancements. By registering with services like Join Dementia Research, the British public continues to play a vital role in the global effort to turn dementia into a manageable or preventable condition.
emergency guidance
Participation in research is a long term commitment, but sudden changes in health require immediate clinical action. Call 999 or seek urgent medical help if a person experiences a sudden onset of facial drooping, arm weakness, or slurred speech, as these are signs of a stroke. Additionally, if a person in a trial or with a diagnosis becomes profoundly and suddenly confused, it may be caused by delirium from a severe infection like a urinary tract infection. Rapid shifts in mental state, an inability to wake up, or a sudden loss of coordination are medical emergencies that must be assessed by an emergency medical team immediately.
Can I take part in research if I don’t have dementia?
Yes. Healthy volunteers are essential for research as they act as a control group, allowing scientists to compare healthy brain aging with the changes caused by dementia.
Do I have to travel to London for these trials?
No. While many trials are led by London based universities, most major studies have recruitment centres across England, Scotland, Wales, and Northern Ireland.
Is it safe to participate in a drug trial?
Every trial must receive ethical approval from an independent committee. This ensures the study is well designed and that the safety and well being of participants are protected.
Will I be paid for taking part in research?
Some trials may offer compensation for travel expenses or time, but most people participate as volunteers to help advance medical science.
Can I leave a trial once I have started?
Yes. You are free to withdraw from any research study at any time without giving a reason, and this will not affect the standard of care you receive from the NHS.
How long do these studies usually last?
The duration varies widely. Some involve a single blood test, while others may require regular visits and monitoring over several years.
Authority Snapshot
Dr. Rebecca Fernandez is a UK trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence based approaches such as CBT, ACT, and mindfulness based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well being in 2026.
